Discussing Novel Best-in-Class Inhibitors of RNA Modifying Enzymes in Oncology for Preclinical Progression

Time: 1:30 pm
day: Day Two


  • Targeting different RNA modifying enzymes using in-house established discovery platform to identify and develop novel highly specific small molecule inhibitors for advanced translation and progression into clinic
  • Exploring case studies of preclinical programs of the best, first in class molecules in oncology with the goal of providing novel therapeutic approaches for patients with unmet medical need